S&P Futures
5,892.75 -3.50 (-0.06%) Dow Futures
43,136.00 -41.00 (-0.09%) Nasdaq Futures
20,498.50 -21.00 (-0.10%) Russell 2000 Futures
2,250.50 -5.00 (-0.22%) Crude Oil
70.54 -0.02 (-0.03%) Gold
2,736.30 -2.60 (-0.09%)
Kronos Bio, Inc. (KRON)
| Previous Close | 0.9500 |
| Open | 0.9200 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.9200 - 0.9649 |
| 52 Week Range | 0.6900 - 1.6000 |
| Volume | |
| Avg. Volume | 88,967 |
| Market Cap | 57.883M |
| Beta (5Y Monthly) | 1.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7400 |
| Earnings Date | Nov 11, 2024 - Nov 15, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.13 |
GlobeNewswireKronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors
– Data show that p300 KAT inhibitor KB-9558 was highly selective against human papillomavirus (HPV) oncoproteins E6 and E7, and therefore drove anti-tumor effects – – Poster presentation taking place on Thursday, October 24, 2024 – SAN MATEO, Calif. and CAMBRIDGE, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and autoimmune diseases driven by deregulated transcription, today announced t
- GlobeNewswire
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease
– KB-7898, a p300 KAT inhibitor, is the Company's first development candidate for autoimmune diseases and originates from its proprietary discovery engine that decodes complex transcription factor regulatory networks – – Preclinical data for KB-7898 will be presented at ACR Convergence 2024 – SAN MATEO, Calif. and CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and autoimmune d
